• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
    • Overview
    • Distribution by PR Newswire
    • Cision Communications Cloud®
    • Cision IR
    • Sponsored Placement
    • All Products
  • Contact
    • General Inquiries
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • Sponsored Placement
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

Global Cancer Immunotherapy Report 2017: Building on Initial Successes to Improve Clinical Outcomes - Research and Markets

Research and Markets Logo

News provided by

Research and Markets

Apr 18, 2017, 16:15 ET

Share this article

Share this article


DUBLIN, Apr. 18, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Cancer Immunotherapy: Building on Initial Successes to Improve Clinical Outcomes" report to their offering.

This new report includes an updated discussion of approved and clinical stage agents in immuno-oncology, including recently-approved agents. It also addresses the means by which researchers and companies are attempting to build on prior achievements in immuno-oncology to improve outcomes for more patients. Some researchers and companies refer to this approach as immuno-oncology 2.0. The American Society of Clinical Oncology (ASCO), in its 12th Annual Report on Progress Against Cancer (2017), named Immunotherapy 2.0 as its Advance of the Year.

Nevertheless, metastatic melanoma remains incurable. Furthermore, in many studies in advanced melanoma and other cancers, only a minority of patients have benefited from immunotherapy treatments. Researchers and companies are therefore looking for ways to build on the initial successes of the immuno-oncology field to improve outcomes for more patients, hence the need for an immuno-oncology 2.0.  Agents that are intended to improve the results of treatment with agents like checkpoint inhibitors may also be referred to as second-wave immuno-oncology agents.

As discussed in this report, researchers have found that checkpoint inhibitors produce tumor responses by reactivating TILs (tumor infiltrating lymphocytes)-especially CD8+ cytotoxic T cells. This key observation is perhaps the most important factor driving development of second-wave immuno-oncology strategies. As a result, researchers have been developing biomarkers that distinguish inflamed (i.e., TIL-containing) tumors-which are susceptible to checkpoint inhibitor therapy-from cold tumors, which are not. They have also been working to develop means to render cold tumors inflamed, via treatment with various conventional therapies and/or development of novel agents. These studies are the major theme of second-wave immuno-oncology, or immuno-oncology 2.0.

Highlights of this Report Include:

- Approvals of checkpoint inhibitors
- Biomarkers for checkpoint inhibitor treatments
- Approved and clinical-stage immunotherapy biologics other than checkpoint inhibitors
- Immunotherapy with TIL cells
- Commercialization of TIL therapy
- Adoptive immunotherapy with genetically engineered T cells bearing chimeric antigen receptors (CARs)
- Manufacturing issues with CAR T-cell therapies
- General conclusions on the progress of cellular immunotherapy
- Outlook for cancer immunotherapy

Key Topics Covered:

1: Introduction

- The early history of cancer immunotherapy - Coley's toxins
- Cytokines as immunomodulatory drugs
- Interleukin-2
- Alpha-interferons
- Interleukin-12
- Interleukin-12 as a bridge between innate and adaptive immunity
- Investigation of interleukin-12 as an anticancer therapeutic
- Interleukin-10
- Interleukin-15
- Admune/Novartis' heterodimeric IL-15:IL-15Ra (hetIL-15)
- Altor's ALT-803
- Conclusions: Cytokine-based immunotherapies for cancer

2: What are immune checkpoints?

- CTLA-4 blocking agents
- Ipilimumab
- Tremelimumab
- PD-1 blocking agents
- Nivolumab
- Combination therapy of nivolumab plus ipilimumab in melanoma
- Pembrolizumab
- Pembrolizumab as a first-line treatment for advanced NSCLC
- Pembrolizumab in colorectal carcinoma with mismatch-repair deficiency
- Studies of pembrolizumab in combination immunotherapies
- PDR001
- PD-L1 blocking agents
- Atezolizumab
- Atezolizumab in treatment of urothelial carcinoma
- Atezolizumab for the treatment of NSCLC
- Atezolizumab in treatment of other solid tumors
- Other anti-PD-L1 mAb agents
- Durvalumab
- Avelumab
- Anti-LAG-3 agents
- anti-TIM-3
- NewLink Genetics' small-molecule IDO pathway inhibitors and checkpoint inhibition
- Infinity's PI3K? inhibitor IPI-549 for modulation of immune suppression in tumors
- Biomarkers for checkpoint inhibitor treatments
- Target biomarkers
- Genetic biomarkers
- Immunological biomarkers
- Use of biomarker tests in treatment with checkpoint inhibitors
- Checkpoint inhibitors plus radiation therapy
- Checkpoint inhibitors plus targeted therapies
- Checkpoint inhibitors with cytotoxic chemotherapies
- Discussion

3: Immune Agonists

- Celldex Therapeutics' Varlilumab (CDX-1127)
- OX40 agonists
- MedImmune/AZ's OX40 agonist program
- Roche/Genentech's OX40 agonist program
- Nektar Therapeutics/BMS's NKTR-214, a CD122 agonist
- Glucocorticoid-induced TNFR-related (GITR) protein agonist (Leap Therapeutics' TRX518)
- Conclusions

4: Bispecific antibodies

- Marketed bispecific antibody agents
- Catumaxomab
- Blinatumomab
- Bispecific antibodies as an alternative to CAR-T cells
- Xencor's cross-linking monoclonal antibody (XmAb) bispecific platform technology
- Regeneron's native human immunoglobulin-format bsAb, REGN1979
- Roche/Genentech's full-length bsAbs: Generated using CrossmAb technology
- MacroGenics' MGD007: Generated using dual-affinity re-targeting (DART) technology
- Conclusions

5: Therapeutic Anticancer Vaccines and Oncolytic viruses

- Introduction
- Cancer vaccines-a field rife with clinical failures
- Why has the cancer vaccine field been so prone to clinical failure?
- Marketed therapeutic cancer vaccines and oncolytic virus therapies
- Dendreon/Valeant's sipuleucel-T
- Amgen's talimogene laherparepvec (T-Vec)/Imlygic
- Therapeutic cancer vaccines and oncolytic virus therapies in clinical development
- Celldex's CDX-1401
- Bavarian Nordic's PROSTVAC-VF
- Argos Therapeutics' AGS-003
- Sydys Corporation's CVac
- Aduro Biotech's CRS-207
- TapImmune's TPIV110 HER2/neu and TPIV200 folate receptor alpha multi-epitope vaccines
- Genelux's GL-ONC1 oncolytic virus
- Conclusions

6: Adoptive Immunotherapy for Cancer

- Introduction
- Adoptive immunotherapy with tumor infiltrating lymphocytes
- A specific immunodominant mutation in a melanoma patient who had a durable complete remission due to TIL therapy
- Adoptive immunotherapy based on mutation-specific CD4+ T cells in an epithelial cancer
- Successful targeting of KRAS G12D via adoptive immunotherapy in a case of metastatic colorectal cancer
- Dr. Rosenberg's recent studies on neoantigen-reactive TILs for use in adoptive cellular immunotherapy
- Commercializing TIL therapy
- Adoptive immunotherapy with genetically engineered T cells bearing chimeric antigen receptors (CARs)
- Leading clinical programs in CAR T-cell based immunotherapy
- Kite Pharma's KTE-C19 (axicabtagene ciloleucel)
- Novartis' CTL019
- Juno's JCAR015 and other Juno anti-CD19 CARs
- Other CAR T-cell therapies that target hematologic malignancies
- bluebird bio's bb2121 for multiple myeloma
- CAR T-cell therapies that target solid tumors
- Novartis/University of Pennsylvania's CARTmeso
- EGFRvIII CAR T-cell therapies
- Companies developing engineered improvements in CAR T-cell therapy
- Bellicum Pharmaceuticals' technologies for modulation of CAR T-cell therapies
- Cellectis' technologies for design and manufacture of off-the shelf CAR T-cell therapies
- Manufacturing issues with CAR T-cell therapies
- Can bispecific antibodies be competitive with CAR T-cell therapies?
- Adptimmune recombinant TCR clinical candidates
- Kite Pharma recombinant TCR program
- Juno Therapeutics' recombinant TCR program
- Recombinant TCR studies at the NCI
- Conclusions
- Market size estimates for the T-cell therapy market

7: General Conclusions

- Major theme of this report: Immuno-oncology 2.0 or second-wave immuno-oncology
- Approvals of checkpoint inhibitors
- Biomarkers for checkpoint inhibitor treatments
- Approved and clinical-stage immunotherapy biologics other than checkpoint inhibitors
- Immunotherapy with TIL cells
- Commercialization of TIL therapy
- Adoptive immunotherapy with genetically engineered T cells bearing chimeric antigen receptors (CARs)
- Manufacturing issues with CAR T-cell therapies
- Adoptive immunotherapy via autologous recombinant TCR technology
- General conclusions on the progress of cellular immunotherapy
- Insight Pharma Reports survey on cancer immunotherapy
- Outlook for cancer immunotherapy

For more information about this report visit http://www.researchandmarkets.com/research/rkf8pp/cancer

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com

Modal title

Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2022 Cision US Inc.